NASDAQ NMS - GLOBAL MARKET · LQDA
-0.91% · -$0.8200 · Vol Not reported
Pre-market · updated 08:54:44 ET
Liquidia Corp

Liquidia Corp

Pharmaceuticals
$89.40
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
LQDA
Liquidia Corp
Fri Aug 7 · last completed session · Pre-market · regular session opens 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

69/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Fri Aug 7 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is LQDA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading LQDA catalysts
About Liquidia Corp
PHARMACEUTICAL PREPARATIONS
Listed since
2018
Employees
216
Country
US

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$90.22
Last session
Day high
$90.22
Last session
Day low
$90.22
Last session
Previous close
$90.22
52W high
$90.22
-0.91% from high
52W low
$21.20
99% of range
Market cap
$8B
P/E
359.70×
EPS
$-0.4600
Beta
0.82
Shares out
88.9M
Avg volume
1.5M
VWAP
$90.22
Last session
Price history computed in-house
1W
+6.62%
1M
+14.72%
3M
+57.95%
1Y
+337.16%
YTD
+159.21%
SMA 50 $75.94 · above
SMA 200 $46.56 · above
52W position 99%

LQDA overview

Veridion Score
69
5 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around LQDA.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading LQDA Form 4 filings
Public disclosures

Congress activity in LQDA

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for LQDA in the cached public ledger.

Federal contracts

LQDA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for LQDA in this window.
Lobbying spend

LQDA lobbying filings, year to date.

Registered lobbying filings matched to Liquidia Corp.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for LQDA in this window.
Loading news for LQDA
Analyst ratings
Sovereign unlock shows live analyst consensus for LQDA.
Options
Sovereign unlock shows live options positioning for LQDA.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.